Dynamic MRI evaluation of the triple receptor tyrosine kinase inhibitor BIBF 1120 in patients with advanced solid tumours
Taylor N, Stirling J, Padhani A, Leach M, d'Arcy J, Collins D, Rustin G, Koh D, Tang A, Knowles B, Lee C, Wallace T, Temple G
Mount Vernon Hospital
Antivascular effects of a triple receptor tyrosine kinase inhibitor (BIBF-1120 acting against VEGF, FGF and PDGF) are explored by dynamic MRI (DCE-MRI) in a multicentre phase I clinical study. Antiangiogenesis effects are seen in isolated patients and in cohort analyses. There was no clear evidence for drug dose dependence but patients with metastatic liver disease appeared to have the largest antivascular effects.